Akasi Pharma ApS
CVR 45364577 · Private limited company (ApS) · Active · Medium risk
Akasi Pharma ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 1 annual report has been published. The latest annual report (31 Dec 2025) shows equity of DKK -1.6m and a net result of DKK -1.6m. CEO: Walden Emil Bjørn-Yoshimoto, Helena Safavi-Hemami.
Bankruptcy risk for Akasi Pharma ApS
1.0 × the average (1.41%) · higher risk than 75% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 45364577
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (1 years)
- Address
- c/o BioInnovation Institute, Ole Maaløes Vej 3
2200 København N - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 56k
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 1 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -63.2% |
| Current ratio | 4,343% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 167 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 |
|---|---|
| Revenue | DKK 1.0m |
| Gross profit | DKK -714k |
| Net profit | DKK -1.6m |
| Equity | DKK -1.6m |
| Total assets | DKK 2.5m |
| Cash | DKK 2.4m |
| Short-term debt | DKK 57k |
Latest annual report: Reporting class B, mikrovirksomhed · auditor's statement: No assurance.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 29 Jan 2025 – 31 Dec 2025 | 71 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Walden Emil Bjørn-Yoshimoto | Current | |
| CEO | Helena Safavi-Hemami | Current | |
| Owner (50%) | Walden Holding ApS | Current | |
| Owner (10%) | Sophie Holding ApS | Current | |
| Owner (25%) | Venimic LLC | Current | |
| Owner (33%) | Venimic LLC | ||
| Founder | Walden Holding ApS | Current | |
| Founder | Venimic LLC | Current |
The CEOs' other companies
Walden Emil Bjørn-Yoshimoto – 1 other companies
- Walden Holding ApS Active
Address history (0 moves)
| c/o BioInnovation Institute, Ole Maaløes Vej 3, 2200 København N |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- AffiCon ApS Valby
- EXTITUTION ApS København Ø
- Coco Sense ApS København NV
- Everllence Denmark A/S København SV
- BioSpectre ApS København V
- Nordic Cell Therapy Group ApS København N
- FiberSure ApS København Ø
- Tasira ApS København N
- Xenogen ApS København S
- Magnalev Core ApS København SV
- Pin Joint ApS København S
- Maglya ApS København Ø
Questions and answers about Akasi Pharma ApS
Has Akasi Pharma ApS gone bankrupt?
No, Akasi Pharma ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Akasi Pharma ApS?
Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.
Who is the CEO of Akasi Pharma ApS?
Walden Emil Bjørn-Yoshimoto, Helena Safavi-Hemami are the CEOs of Akasi Pharma ApS.
When was Akasi Pharma ApS founded?
Akasi Pharma ApS was founded on 29 January 2025.
What is the equity of Akasi Pharma ApS?
Equity was DKK -1.6m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.